Trevena Announces Advancement of Oliceridine Clinical Development in China by Jiangsu Nhwa Pharmaceutical Co.
03 juin 2020 08h02 HE
|
Trevena Inc.
CHESTERBROOK, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients
02 juin 2020 07h00 HE
|
Trevena Inc.
-- TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung injury and ARDS Robust clinical development history with well-characterized PK and demonstrated safety in...
Trevena Reports First Quarter 2020 Results
07 mai 2020 07h00 HE
|
Trevena Inc.
Trevena Reports First Quarter 2020 ResultsFDA review of oliceridine NDA ongoing; PDUFA date August 7, 2020 IND filing for novel S1P modulator (TRV045) in 1H 2021; ongoing collaboration with NIH to...
Trevena to Release First Quarter 2020 Financial Results on May 7, 2020
01 mai 2020 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Publication of Comprehensive Review of Oliceridine Data
23 avr. 2020 07h00 HE
|
Trevena Inc.
Overview of clinical and nonclinical data to date for oliceridine; includes efficacy data in hard- and soft- tissue surgeries, safety / tolerability data in high-risk patients CHESTERBROOK, Pa.,...
Trevena Reports Fourth Quarter and Full Year 2019 Results
12 mars 2020 07h01 HE
|
Trevena Inc.
PDUFA date of August 7, 2020 for IV oliceridine; FDA considers NDA resubmission complete Initiated proof-of-concept studies for acute migraine (TRV250) and opioid use disorder (TRV734) Announces NIH...
Trevena to Report Fourth Quarter and Full Year 2019 Results on March 12, 2020
05 mars 2020 17h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces FDA Has Set PDUFA Date of August 7, 2020 for Oliceridine
05 mars 2020 07h01 HE
|
Trevena Inc.
FDA considers NDA resubmission a complete Class 2 response Updated guidance on extended cash runway, funding operations into Q1 2021 CHESTERBROOK, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Trevena,...
Trevena Appoints Scott Applebaum as Chief Legal and Compliance Officer and SVP of Regulatory Affairs
13 févr. 2020 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Resubmits New Drug Application for Oliceridine
10 févr. 2020 07h01 HE
|
Trevena Inc.
CHESTERBROOK, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...